Human CD30/TNFRSF8 (MDX-1401) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Tumor necrosis factor receptor superfamily member 8 (CD30/TNFRSF8) is a ~63 kDa protein. Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. CD30 is the therapeutic target of brentuximab vedotin (Adcetris).
Product Name:
Human CD30/TNFRSF8 (MDX-1401) Antibody
SKU:
GXBS01047
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Clone:
MDX-1401
Target:
CD30L receptor
Isotype:
IgG
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FACS, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
MDX-1401, MDX1401, MDX1401
Biological Activity:
MDX-1401 binds to recombinant CD30 with a K d value of 0.83 nmol/L, exhibiting binding affinity comparable to that of its parental antibody MDX-060 [1]. MDX-1401 (125 I-MDX-1401) binds to CD30 on the surface of the Hodgkin's lymphoma cell line L540 cells, with a K d value of approximately 1.9 nmol/L [1]. MDX-1401 (0.012-50 ug/mL; 30 min primary incubation, 30 min secondary incubation) binds to CD30 + lymphoma cell lines (L540, Karpas-299, L428, L1236) in a dose-dependent manner, and its binding properties are consistent with those of the parental antibody MDX-060 [1]. MDX-1401 mediates FcγRIIIa-dependent antibody-dependent cellular cytotoxicity (ADCC) against L540 Hodgkin lymphoma cells, with an EC 50 of 0.009 ug/mL and a maximum cell lysis rate of 87%, exhibiting superior potency and efficacy compared to the parental antibody MDX-060 [1]. MDX-1401 (treated at 37°C for 4 h) mediates dose-dependent ADCC against CD30 + lymphoma cell lines (L540, Karpas-299, L428, L1236), with EC 50 values ranging from 0.008 to 0.04 ug/mL and maximum lysis rates of 13% to 68%. This includes activity against L1236 cells with low CD30 expression, against which the parental antibody MDX-060 shows no activity [1]. MDX-1401 binds to CD30 on L540 Hodgkin lymphoma cells with a K D value of 1.9 nM, and its antigen-binding affinity is nearly identical to that of its parental antibody MDX-060 (K D ~1.4 nM) [2]. MDX-1401 mediates significantly stronger and more effective ADCC against CD30-expressing tumor cell lines (including those with low CD30 expression) across all FcgRIIIa polymorphic variants, with a decreased EC 50 and an increased maximum specific lysis rate compared to its parental antibody [2]. MDX-1401 (1 mg/kg; i.p.; single dose) significantly prolongs the survival of SCID mice with systemic Karpas-299 ALCL [1].
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
